// App-Quantinova.ai

3564 : Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).

Researchers

Presenter

  • Bert H. O'Neil

Principal Investigators

  • Joleen Marie Hubbard

  • Alexander Starodub

  • Derek J. Jonker

  • William Jeffery Edenfield

  • Bassel F. El-Rayes

  • Thorvardur Ragnar Halfdanarson

  • Ramesh K. Ramanathan

  • Henry C. Pitot

  • Carolyn D. Britten

  • Bamidele Adesunloye

  • Axel Grothey

  • Laura Borodyansky

  • Chiang Li

Medical Centers

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Mayo Clinic, Rochester, MN

  • Indiana University Health Center for Cancer Care, Goshen, IN

  • Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada

  • Institute for Translational Oncology Research, Greenville Hospital System/University Medical Center, Greenville, SC

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Mayo Clinic, Scottsdale, AZ

  • Mayo Clinic Cancer Center, Scottsdale, AZ

  • Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • National Institute of Health, Westfiled, IN

  • Boston Biomedical Inc., Cambridge, MA

Locations

  • United States

  • Canada

Companies

  • Boston Biomedical, I

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Napabucasin

  • Irinotecan

  • leucovorin

  • FOLFIRI

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02024607

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved